

INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-01201	Serial No: 09/ 436,347
	Inventor(s): Christine WHITE <i>et al.</i>	Examiner: A.M. HARRIS
	Filed: 28 July 2000	Art Unit: 1643

U.S. PATENT DOCUMENTS

INITIAL	INDEX	DOCUMENT	DATE	NAME	CLASS	SUB.	FILING DATE
	D324	4,816,397	28 Mar 1989	Boss			
	D325	4,816,567	28 Mar 1989	Cabilly			
	D326	5,225,535	6 Jul 1993	Winter			
	D327	5,250,732	5 Oct 1993	Kogan			
	D328	5,530,101	25 Jun 1996	Queen			
	D329	5,691,135	25 Nov 1997	Braun			
	D330	6,399,649 B1	7 Aug 2003	Anderson			
	D331	7,381,560 B2	3 Jun 2008	Anderson			
	D332	7,422,739 B2	9 Sep 2008	Anderson			
	D333	2008/0038261 A1	14 Feb 2008	Grillo-López			

FOREIGN PATENT DOCUMENTS

INITIAL	INDEX	DOCUMENT	DATE	COUNTRY	CLASS	SUB.	TRANSLATION	
							YES	NO
	D334	0 274 394 A2	13 Jul 1988	EP				
	D335	94/ 08601	28 Apr 1994	WO				
	D336	98/ 42378	1 Oct 1998	WO				

EXAMINER /Alana M. Harris/	DATE CONSIDERED 11 February 2009
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	SHEET 1 OF 4

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AH/

INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-01201	Serial No: 09/ 436,347
	Inventor(s): Christine WHITE <i>et al.</i>	Examiner: A.M. HARRIS
	Filed: 28 July 2000	Art Unit: 1643

OTHER DOCUMENTS

INITIAL	INDEX	CITATION
	D337	Alas S. et al. <i>Anticancer Res.</i> 20(5A): 2961-66, 2000. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.
	D338	Arranz R. et al. <i>J. Clin. Oncol.</i> 16(4): 1538-46, 1998. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.
	D339	Belhadj K. et al. <i>Ann. Oncol.</i> 15: 504-10, 2004. Efficiency of <i>in vivo</i> purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study.
	D340	Berinstein N. et al. <i>Proc. Amer. Assn. Cancer Res.</i> 38: 85, abst. no. 567, March 1997. IDEC-C2B8 (rituximab) levels correlate with response in low-grade or follicular non-Hodgkin's lymphoma (LG-F-NHL).
	D341	Bierman P.J. et al. (in) Hoffman, R., ed., <i>Hematology</i> , 2d. ed. (Churchill Livingstone), 1995. Chapter 81, pages 1278-98. Clinical manifestations and staging of and therapy for non-Hodgkin's lymphomas.
	D342	Byrd J.C. <i>Cancer Biother. Radiopharm.</i> 14(4)L 323, 1999. Rituximab therapy in patients with chronic lymphocytic leukemia.
	D343	Cheson B.D. et al. <i>Blood</i> 87: 4990-97, 1996. National Cancer Institute-specified working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.
	D344	Chow K.U. et al. <i>Haematologica</i> 87: 33-43, 2002. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes <i>in vitro</i> : role of cytokines, complement, and caspases.
	D345	Eisenbeis C.F. et al. <i>Clin. Cancer Res.</i> 10: 6101-10 (2004). Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
	D346	Engert A. et al. <i>Ann. Hematol.</i> 77(suppl. 2): S180, abst. no. 717. Multicenter phase II study of the monoclonal anti-CD20 antibody rituximab (IDEC-C2B8) in patients with intermediate/high grade non-Hodgkin's lymphoma.
	D347	Foran J.M. et al. <i>Br. J. Haematol.</i> 102(1): 149, 1998. Immunotherapy of mantle cell lymphoma (MCL), lymphoplasmacytoid lymphoma (LPC) and Waldentrom's macroglobulinemia (WM), and small lymphocytic leukemia (SLL) with rituximab (IDEC-C2B8): preliminary results of an ongoing international multicentre trial.

EXAMINER /Alana M. Harris/	DATE CONSIDERED 11 February 2009
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	SHEET 2 OF 4

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AH/

INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-01201	Serial No: 09/ 436,347
	Inventor(s): Christine WHITE <i>et al.</i>	Examiner: A.M. HARRIS
	Filed: 28 July 2000	Art Unit: 1643

D348	Fridik M.A. et al. <i>Ann. Hematol.</i> 74(1): 7-10, 1997. First-line treatment of Waldenström's disease with cladribine.
D349	Gianni A.M. et al. <i>Blood</i> 102: 749-55, 2003. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).
D350	Ginaldi L. et al. <i>J. Clin. Pathol.</i> 51: 364-69, 1998. Levels of expression of CD19 and CD20 in chronic B leukaemias.
D351	Golay J. et al. <i>Haematologica</i> 88: 1002-12, 2003. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.
D352	Gribben J.G. et al. <i>N. Engl. J. Med.</i> 325(22): 1525-32, 1991. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma.
D353	Hillmen P. et al. <i>Semin. Oncol.</i> 31(1 suppl. 2): 22-26, 2004. Advancing therapy for chronic lymphocytic leukemia – the role of rituximab.
D354	IDEC Pharmaceuticals Corp., press release dated 9 December 1996. IDEC Pharmaceuticals and Genentech announce positive final results for pivotal phase III trial of IDEC-C2B8 as single agent.
D355	Imrie, K. et al. <i>Curr. Oncol.</i> 6(4): 228-35, 1999. Use of rituximab in the treatment of lymphoma: an evidence summary.
D356	Jazirehi A.R. et al. <i>Oncogene</i> 24: 2121-43, 2005. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
D357	Keating M. et al. <i>Semin. Oncol.</i> 27(6 suppl. 12): 86-90, 2000. High-dose rituximab therapy in chronic lymphocytic leukemia.
D358	Maddy A.H. et al. <i>Immunol.</i> 68(3): 346-52, 1989. The role of cell maturation in the generation of phenotypic heterogeneity in B-cell chronic lymphocytic leukaemia.
D359	Marti G.E. et al. <i>Ann. N.Y. Acad. Sci.</i> 651: 480-83, 1992. CD20 and CD5 expression in B-chronic lymphocytic leukemia.
D360	Mazza P. et al. <i>Bone Marrow Trans.</i> 23: 1273-78, 1999. Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: an interim report.
D361	Nguyen D.T. et al. <i>Eur. J. Haematol.</i> 62: 76-82, 1999. IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients.

EXAMINER /Alana M. Harris/	DATE CONSIDERED 11 February 2009
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	SHEET 3 OF 4

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AH/

INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-01201	Serial No: 09/ 436,347
	Inventor(s): Christine WHITE <i>et al.</i>	Examiner: A.M. HARRIS
	Filed: 28 July 2000	Art Unit: 1643

	D362	O'Brien S.M. et al. <i>J. Clin. Oncol.</i> 19: 2165-70, 2001. Rituximab dose-escalation trial in chronic lymphocytic leukemia.
	D363	Piro L. et al. <i>Blood</i> 90(10 Suppl. 1): 510a, abst. no. 2272, 1997. RITUXAN TM (rituximab, IDEC-C2B8): Interim analysis of a phase II study of once weekly times 8 dosing in patients with relapsed low-grade or follicular non-Hodgkin's lymphoma.
	D364	Rai K.R. et al. (in) R. Hoffman, R., ed., <i>Hematology</i> , 2d. ed. (Churchill Livingstone), 1995. Chapter 83, pages 1308-19. Chronic lymphocytic leukemia.
	D365	Saville, M.W. Statement of M. Wayne Saville, M.D., dated 20 December 2007, submitted by applicant in Taiwan (R.O.C.) patent application no. 088119557.
	D366	van der Kolk, L.E. et al. <i>Blood</i> 92(10 Suppl. 1): 512a-513a, abst. no. 2284, 1997. Phase I/II clinical trial to evaluate the safety and efficacy of a chimeric anti-CD20 monoclonal antibody (rituximab) and G-CSF given weekly to patients with relapsed B-cell lymphoma.
	D367	Witzig T.E. et al. <i>Am. J. Clin. Pathol.</i> 101: 312-17, 1994. Measurement of the intensity of cell surface antigen expression in B-cell chronic lymphocytic leukemia.
	D368	Zhou X. et al. <i>Chinese Pharm. J.</i> 30(8): 453-54, 1995. 细胞因子疗法在肿瘤治疗中的应用. (English translation of abstract provided.)

EXAMINER /Alana M. Harris/	DATE CONSIDERED 11 February 2009
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
Form PTO-1449 (modified)	SHEET 4 OF 4

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AH/